# BETTER TOGETHER

## Smarter PCV spending. More protection against RSV.

## THE GAMBIA



Pneumonia is the second leading killer of children under five in The Gambia, causing 460 deaths in 2024 according to UNICEF. Pneumococcus and respiratory syncytial virus (RSV) are leading bacterial and viral causes of childhood pneumonia respectively.

The Gambia already vaccinates children against pneumococcus with pneumococcal conjugate vaccine (PCV). Now, a new maternal RSV vaccine offers the opportunity to protect babies against RSV too.

The Gambia is currently exploring optimizing its PCV program by switching product or by reducing doses, both of which would generate savings to help fund this additional protection.


This brief uses the new PCV-OPTIMISE tool, development at the University of Melbourne, Australia, to estimate the savings to The Gambia and to Gavi, the Vaccine Alliance from these PCV optimization options.

It also presents the latest estimates of The Gambia RSV burden, underscoring the case for reinvesting PCV 1+1 savings in maternal RSV vaccination.

Better together, these two vaccines will help The Gambia prevent more pneumonia, reduce hospitalizations, and save more children's lives - while making existing resources go further.



### LEADING CAUSES OF CHILD DEATH IN THE GAMBIA, 2024




Source: United Nations Inter-agency Group for Child Mortality Estimation (UN IGME), 2026

STOP RSV


SECURE PCV

EVERY BREATH COUNTS

# BETTER TOGETHER

**Smarter PCV spending. More protection against RSV.**

## THE GAMBIA



## PCV PROGRAM AND COVERAGE IN THE GAMBIA, 2021-2025

- *Prevenar 13*
- *4 dose vial*
- *Introduced 2009*
- *3+0 schedule*

Source: View-hub by IVAC

| PCV Coverage | 2025 | 2024 | 2023 | 2022 | 2021 | Average |
|---|---|---|---|---|---|---|
| PCV (3 doses) | 82% | 80% | 80% | 75% | 78% | 75% |

Source: WHO, UNICEF Estimates of National Immunization Coverage (WUENIC), 2026

## PCV OPTIMIZATION SAVINGS

PCV-OPTIMISE compares the costs of The Gambia's current PCV program - three doses of Prevenar 13 - between 2026 and 2030, with three optimization scenarios.

Here are the results (all numbers rounded):

1. Switching to three doses of Pneumosil reduces costs from US$5 million to US$3.5 million, saving US$1.4 million (28%). The Gambia saves US$0.1 million and Gavi saves US$1.3 million. This option requires 3% less cold-chain space.

2. Switching to two-doses (1+1) of Prevenar 13 reduces costs from US$5 million to US$3 million, saving US$1.8 million (36%). The Gambia saves US$0.3 million and Gavi saves US$1.5 million. This option requires 36% less cold-chain space.

3. Switching to two-doses (1+1) of Pneumosil reduces costs from US$5 million to US$2.3 million, saving US$2.6 million (52%). The Gambia saves US$0.3 million and Gavi saves US$2.3 million. This option requires 58% less cold-chain space.

The Gambia is in Gavi's *initial self-financing* phase where the government pays 7% of vaccine costs with Gavi covering 93%.

*Countries planning both a PCV product and a schedule change should pursue a staged transition, with the sequence determined by national vaccine authorities based on local evidence and program readiness.*

STOP RSV

SECURE PCV

EVERY BREATH COUNTS

# BETTER TOGETHER

**Smarter PCV spending. More protection against RSV.**

## THE GAMBIA

## PCV AND RSV MATERNAL VACCINE

PCV and maternal RSV vaccines are better together because they strengthen protection against major bacterial and viral causes of pneumonia, especially during babies' vulnerable first six months.

Research suggests that protection against these two pathogens may be mutually reinforcing: pneumococcal vaccination has been associated with fewer RSV hospitalizations, while a French study linked RSV prevention using the antibody nirsevimab to fewer hospitalizations for invasive pneumococcal disease.


The estimated US$1.8 million savings from switching to two-dose Prevenar create an opportunity for The Gambia to reap these gains by introducing maternal RSV vaccination.

At a price of US$3.50 per dose, these savings could purchase maternal RSV vaccine for all for all 410,361 projected pregnancies in The Gambia during 2026–2030, leaving approximately US$0.32 million toward delivery, wastage, and freight.

Realizing this opportunity would require Gavi to make its share of PCV savings available to support maternal RSV vaccination—giving The Gambia a practical route to protect more children with existing resources and advance national child survival goals.



### PCV OPTIMIZATION SAVINGS IN THE GAMBIA, 2026-2030




Source: PCV-OPTIMISE. The University of Melbourne, 2026

STOP RSV

SECURE PCV

EVERY BREATH COUNTS

# BETTER TOGETHER

**Smarter PCV spending. More protection against RSV.**

## THE GAMBIA



## WHY IS RSV PREVENTION SO IMPORTANT FOR THE GAMBIA?

Over the next decade RSV will sicken an estimated 185,000 million children under five in The Gambia, hospitalizing 18,500 and killing 800, absent introduction of the new prevention tools.

This not only places a heavy burden on families but also on the health system, as hospital wards fill with sick children during RSV season each year.


In a clinical trial, maternal RSV vaccination resulted in 70% fewer babies developing severe RSV disease during their first six months, with an exploratory analysis reported 31% fewer hospitalizations for pneumonia from any cause.

In real-world studies, maternal RSV vaccination was associated with 85% fewer RSV hospitalizations in England and 87% fewer RSV intensive care admissions among babies under six months in Argentina.

The World Health Organization recommends all countries introduce either maternal RSV vaccination, given from 28 weeks of pregnancy onwards, or a long-acting antibody for infants.

Gavi accepts applications from eligible countries, including The Gambia, for support to introduce maternal RSV vaccination.

### RSV BURDEN AMONG CHILDREN IN THE GAMBIA, 2026-2035




Source: Clark, AD et al, 2026 (unpublished, forthcoming)

## Explore PCV-OPTIMISE!

*This brief was prepared by the Every Breath Counts Coalition for the Better Together campaign. To learn more, visit StopPneumonia.org.*

*November 2026*

STOP RSV

SECURE PCV

EVERY BREATH COUNTS